Metastatic Pancreatic Cancer - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 354 pages

Metastatic Pancreatic Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Metastatic Pancreatic Cancer - Pipeline Review, H1 2015’, provides an overview of the Metastatic Pancreatic Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Metastatic Pancreatic Cancer - Pipeline Review, H1 2015
Table of Contents
Table of Contents 2
Introduction 8
Global Markets Direct Report Coverage 8
Metastatic Pancreatic Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Metastatic Pancreatic Cancer - Overview 10
Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis 11
Metastatic Pancreatic Cancer - Therapeutics under Development by Companies 12
Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 17
Metastatic Pancreatic Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Metastatic Pancreatic Cancer - Products under Development by Companies 21
Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes 26
Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development 27
AbbVie Inc. 27
Aduro BioTech, Inc. 28
AstraZeneca PLC 29
AVEO Pharmaceuticals, Inc. 30
Axcentua Pharmaceuticals AB 31
Bayer AG 32
BioCancell Therapeutics, Inc. 33
Boehringer Ingelheim GmbH 34
Boston Biomedical, Inc. 35
Cantex Pharmaceuticals, Inc. 36
Celgene Corporation 37
Colby Pharmaceutical Company 38
Cornerstone Pharmaceuticals, Inc. 39
Eleison Pharmaceuticals, Inc. 40
Eli Lilly and Company 41
F. Hoffmann-La Roche Ltd. 42
FibroGen, Inc. 43
Fountain Biopharma Inc. 44
Gilead Sciences, Inc. 45
GlaxoSmithKline plc 46
Halozyme Therapeutics, Inc. 47
Immunomedics, Inc. 48
Incyte Corporation 49
Merck and Co., Inc. 50
Merck KGaA 51
Merrimack Pharmaceuticals, Inc. 52
Momenta Pharmaceuticals, Inc. 53
NanoCarrier Co., Ltd. 54
Nanotherapeutics, Inc. 55
NewLink Genetics Corporation 56
Novartis AG 57
Oncolytics Biotech Inc. 58
OncoMed Pharmaceuticals, Inc. 59
Oncovir, Inc. 60
Oncozyme Pharma Inc. 61
Pfizer Inc. 62
Pharma Mar, S.A. 63
Precision Biologics, Inc. 64
Regulon Inc. 65
Rexahn Pharmaceuticals, Inc. 66
Sanofi 67
Silence Therapeutics plc 68
Synta Pharmaceuticals Corp. 69
Takeda Oncology 70
Teva Pharmaceutical Industries Limited 71
Threshold Pharmaceuticals, Inc. 72
Metastatic Pancreatic Cancer - Therapeutics Assessment 73
Assessment by Monotherapy Products 73
Assessment by Combination Products 74
Assessment by Target 75
Assessment by Mechanism of Action 78
Assessment by Route of Administration 81
Assessment by Molecule Type 83
Drug Profiles 85
Atu-027 - Drug Profile 85
AXP-10711 - Drug Profile 87
BBI-608 - Drug Profile 89
BC-819 - Drug Profile 91
bevacizumab - Drug Profile 93
BI-853520 - Drug Profile 98
binimetinib - Drug Profile 100
CEP-37250 - Drug Profile 104
CIM-1 - Drug Profile 105
cisplatin - Drug Profile 106
cisplatin liposomal - Drug Profile 108
clivatuzumab tetraxetan - Drug Profile 110
CPC-410 - Drug Profile 112
CPI-613 - Drug Profile 113
CRS-207 - Drug Profile 115
demcizumab - Drug Profile 117
Dendritic Cell Therapy for Cancer - Drug Profile 121
ensituximab - Drug Profile 122
erismodegib - Drug Profile 124
evofosfamide - Drug Profile 127
FB-704A - Drug Profile 134
FG-3019 - Drug Profile 135
ficlatuzumab - Drug Profile 137
galunisertib - Drug Profile 140
ganetespib - Drug Profile 142
glufosfamide - Drug Profile 146
indoximod - Drug Profile 148
irinotecan sucrosofate liposomal - Drug Profile 150
lapatinib ditosylate - Drug Profile 153
LCL-161 - Drug Profile 157
LGK-974 - Drug Profile 159
lurbinectedin - Drug Profile 160
LY-2109761 - Drug Profile 162
LY-2495655 - Drug Profile 163
MesoCART - Drug Profile 164
MK-2206 - Drug Profile 165
MK-2206 + selumetinib sulfate - Drug Profile 168
MLN-0264 - Drug Profile 170
necuparanib - Drug Profile 171
nimotuzumab - Drug Profile 172
olaparib - Drug Profile 175
paclitaxel albumin bound - Drug Profile 179
paclitaxel lipsomal - Drug Profile 183
PD-0325901 + PF-05212384 - Drug Profile 185
PEGPH-20 - Drug Profile 186
pelareorep - Drug Profile 187
pentamidine isethionate - Drug Profile 192
PGX-100 - Drug Profile 194
pimasertib hydrochloride - Drug Profile 196
plerixafor - Drug Profile 198
Poly-ICLC - Drug Profile 200
PRI-724 - Drug Profile 202
refametinib - Drug Profile 204
rottlerin - Drug Profile 207
ruxolitinib phosphate - Drug Profile 208
RX-0201 - Drug Profile 213
SGT-53 - Drug Profile 215
SiG12D-LODER - Drug Profile 216
simtuzumab - Drug Profile 218
Small Molecules to Inhibit Lysyl Oxidase for Metastatic Pancreatic Cancer - Drug Profile 220
Stem Cell Therapy for Oncology - Drug Profile 221
TL-118 - Drug Profile 222
trametinib dimethyl sulfoxide - Drug Profile 224
Triapine - Drug Profile 227
Vaccine to Target VEGFR-1 and VEGFR-2 for Metastatic Hepatocellular Carcinoma and Metastatic Pancreatic Cancer - Drug Profile 229
veliparib - Drug Profile 230
Metastatic Pancreatic Cancer - Recent Pipeline Updates 233
Metastatic Pancreatic Cancer - Dormant Projects 334
Metastatic Pancreatic Cancer - Discontinued Products 337
Metastatic Pancreatic Cancer - Product Development Milestones 339
Featured News and Press Releases 339
Appendix 348
Methodology 348
Coverage 348
Secondary Research 348
Primary Research 348
Expert Panel Validation 348
Contact Us 349
Disclaimer 349

List of Tables

Number of Products under Development for Metastatic Pancreatic Cancer, H1 2015 15
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H1 2015 16
Number of Products under Development by Companies, H1 2015 18
Number of Products under Development by Companies, H1 2015 (Contd..1) 19
Number of Products under Development by Companies, H1 2015 (Contd..2) 20
Number of Products under Development by Companies, H1 2015 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2015 22
Comparative Analysis by Late Stage Development, H1 2015 23
Comparative Analysis by Clinical Stage Development, H1 2015 24
Comparative Analysis by Early Stage Development, H1 2015 25
Products under Development by Companies, H1 2015 26
Products under Development by Companies, H1 2015 (Contd..1) 27
Products under Development by Companies, H1 2015 (Contd..2) 28
Products under Development by Companies, H1 2015 (Contd..3) 29
Products under Development by Companies, H1 2015 (Contd..4) 30
Products under Investigation by Universities/Institutes, H1 2015 31
Metastatic Pancreatic Cancer - Pipeline by AbbVie Inc., H1 2015 32
Metastatic Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H1 2015 33
Metastatic Pancreatic Cancer - Pipeline by AstraZeneca PLC, H1 2015 34
Metastatic Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 35
Metastatic Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H1 2015 36
Metastatic Pancreatic Cancer - Pipeline by Bayer AG, H1 2015 37
Metastatic Pancreatic Cancer - Pipeline by BioCancell Therapeutics, Inc., H1 2015 38
Metastatic Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 39
Metastatic Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H1 2015 40
Metastatic Pancreatic Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 41
Metastatic Pancreatic Cancer - Pipeline by Celgene Corporation, H1 2015 42
Metastatic Pancreatic Cancer - Pipeline by Colby Pharmaceutical Company, H1 2015 43
Metastatic Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 44
Metastatic Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals, Inc., H1 2015 45
Metastatic Pancreatic Cancer - Pipeline by Eli Lilly and Company, H1 2015 46
Metastatic Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 47
Metastatic Pancreatic Cancer - Pipeline by FibroGen, Inc., H1 2015 48
Metastatic Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H1 2015 49
Metastatic Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H1 2015 50
Metastatic Pancreatic Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 51
Metastatic Pancreatic Cancer - Pipeline by Halozyme Therapeutics, Inc., H1 2015 52
Metastatic Pancreatic Cancer - Pipeline by Immunomedics, Inc., H1 2015 53
Metastatic Pancreatic Cancer - Pipeline by Incyte Corporation, H1 2015 54
Metastatic Pancreatic Cancer - Pipeline by Merck and Co., Inc., H1 2015 55
Metastatic Pancreatic Cancer - Pipeline by Merck KGaA, H1 2015 56
Metastatic Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 57
Metastatic Pancreatic Cancer - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 58
Metastatic Pancreatic Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2015 59
Metastatic Pancreatic Cancer - Pipeline by Nanotherapeutics, Inc., H1 2015 60
Metastatic Pancreatic Cancer - Pipeline by NewLink Genetics Corporation, H1 2015 61
Metastatic Pancreatic Cancer - Pipeline by Novartis AG, H1 2015 62
Metastatic Pancreatic Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015 63
Metastatic Pancreatic Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 64
Metastatic Pancreatic Cancer - Pipeline by Oncovir, Inc., H1 2015 65
Metastatic Pancreatic Cancer - Pipeline by Oncozyme Pharma Inc., H1 2015 66
Metastatic Pancreatic Cancer - Pipeline by Pfizer Inc., H1 2015 67
Metastatic Pancreatic Cancer - Pipeline by Pharma Mar, S.A., H1 2015 68
Metastatic Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H1 2015 69
Metastatic Pancreatic Cancer - Pipeline by Regulon Inc., H1 2015 70
Metastatic Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 71
Metastatic Pancreatic Cancer - Pipeline by Sanofi, H1 2015 72
Metastatic Pancreatic Cancer - Pipeline by Silence Therapeutics plc, H1 2015 73
Metastatic Pancreatic Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 74
Metastatic Pancreatic Cancer - Pipeline by Takeda Oncology, H1 2015 75
Metastatic Pancreatic Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 76
Metastatic Pancreatic Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 77
Assessment by Monotherapy Products, H1 2015 78
Assessment by Combination Products, H1 2015 79
Number of Products by Stage and Target, H1 2015 81
Number of Products by Stage and Mechanism of Action, H1 2015 84
Number of Products by Stage and Route of Administration, H1 2015 87
Number of Products by Stage and Molecule Type, H1 2015 89
Metastatic Pancreatic Cancer Therapeutics - Recent Pipeline Updates, H1 2015 238
Metastatic Pancreatic Cancer - Dormant Projects, H1 2015 339
Metastatic Pancreatic Cancer - Dormant Projects (Contd..1), H1 2015 340
Metastatic Pancreatic Cancer - Dormant Projects (Contd..2), H1 2015 341
Metastatic Pancreatic Cancer - Discontinued Products, H1 2015 342
Metastatic Pancreatic Cancer - Discontinued Products (Contd..1), H1 2015 343

List of Figures

Number of Products under Development for Metastatic Pancreatic Cancer, H1 2015 15
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H1 2015 16
Number of Products under Development by Companies, H1 2015 17
Number of Products under Investigation by Universities/Institutes, H1 2015 22
Comparative Analysis by Clinical Stage Development, H1 2015 24
Comparative Analysis by Early Stage Products, H1 2015 25
Assessment by Monotherapy Products, H1 2015 78
Assessment by Combination Products, H1 2015 79
Number of Products by Stage and Top 10 Targets, H1 2015 80
Number of Products by Top 10 Mechanism of Actions, H1 2015 83
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 83
Number of Products by Top 10 Routes of Administration, H1 2015 86
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 86
Number of Products by Top 10 Molecule Types, H1 2015 88
Number of Products by Stage and Top 10 Molecule Types, H1 2015 88

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • November 2014
  • by Global Data

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023 Summary Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the ...

Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • December 2014
  • by GBI Research

Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation Summary Large and Diverse Pipeline The liver cancer pipeline contains 238 products in active development, approximately ...

Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • November 2014
  • by GBI Research

Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The prostate cancer pipeline is among the largest in the ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.